Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

Targeted therapies such as kinase inhibitors and monoclonal antibodies have dramatically altered cancer care in recent decades. Although these targeted therapies have improved patient outcomes in several cancer types, resistance ultimately develops to these agents. One potential strategy proposed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahronian, Leanne G., Corcoran, Ryan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399860/
https://www.ncbi.nlm.nih.gov/pubmed/28431544
http://dx.doi.org/10.1186/s13073-017-0431-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399860/
https://www.ncbi.nlm.nih.gov/pubmed/28431544
http://dx.doi.org/10.1186/s13073-017-0431-3

Ejemplares similares